Serum anti-müllerian hormone levels in evaluation of chemotherapy effect on ovarian reserve in women with breast cancer

References

1. ↵
   1. Ferlay J,
   2. Shin HR,
   3. Bray F,
   4. Forman D,
   5. Mathers C,
   6. Parkin DM

   (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Jemal A,
   2. Tiwari RC,
   3. Murray T,
   4. Ghafoor A,
   5. Samuels A,
   6. Ward E,
   7. et al.

   (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Iraqi National Cancer Research Center

   (2013) Brief historical introduction, establishing the breast & cervical cancer research unit and the Iraqi National Cancer Research Center/Program (Iraqi National Cancer Research Center, Baghdad (Iraq)).
4. ↵
   1. Partridge AH,
   2. Gelber S,
   3. Peppercorn J,
   4. Sampson E,
   5. Knudsen K,
   6. Laufer M,
   7. et al.

   (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22:4174–4183.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Jamil Z,
   2. Fatima SS,
   3. Ahmed K,
   4. Malik R

   (2016) Anti-mullerian hormone: above and beyond conventional ovarian reserve markers. Dis Markers 2016:5246217.

   OpenUrl
6. ↵
   1. van Disseldorp J,
   2. Faddy MJ,
   3. Themmen AP,
   4. de Jong FH,
   5. Peeters PH,
   6. van der Schouw YT,
   7. et al.

   (2008) Relationship of serum antimüllerian hormone concentration to age at menopause. J Clin Endocrinol Metab 93:2129–2134.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Fréour T,
   2. Barrière P,
   3. Masson D

   (2017) Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur J Cancer 74:1–8.

   OpenUrlCrossRef
8. ↵
   1. Groome NP,
   2. Evans LW

   (2000) Does measurement of inhibin have a clinical role? Ann Clin Biochem 37:419–431.

   OpenUrlCrossRef
9. ↵
   1. Burits CA,
   2. Ashwood ER,
   3. Bruns DE

   (2008) Tietz Fundamentals of Clinical chemistry (Saunders Elsevier, Philadelphia (PA)) and 735-801, 6th ed, pp 373–401.
10. ↵
    1. Bozza C,
    2. Puglisi F,
    3. Lambertini M,
    4. Osa EO,
    5. Manno M,
    6. Del Mastro L

    (2014) Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer 21:R51–R65.

    OpenUrlAbstract/FREE Full Text
11. ↵
    1. D'Avila ÂM,
    2. Capp E,
    3. Corleta HVE

    (2017) Antral Follicles Count and Anti-Müllerian hormone levels after gonadotoxic chemotherapy in patients with breast cancer: cohort study. Rev Bras Ginecol Obstet 39:162–168.

    OpenUrl
12. ↵
    1. Anderson RA,
    2. Rosendahl M,
    3. Kelsey TW,
    4. Cameron DA

    (2013) Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49:3404–3411.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Dillon KE,
    2. Sammel MD,
    3. Prewitt M,
    4. Ginsberg JP,
    5. Walker D,
    6. Mersereau JE,
    7. et al.

    (2013) Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 99:477–483.

    OpenUrlCrossRefPubMed
14. ↵
    1. Fritz MA,
    2. Speroff L

    (2011) Female infertility. Clinical Gynecologic Endocrinology and Infertility (Lippincott Williams and Wilkins, Philadelphia (PA)), 8th ed, pp 1137–1190.
15. ↵
    1. Tikk K,
    2. Sookthai D,
    3. Fortner RT,
    4. Johnson T,
    5. Rinaldi S,
    6. Romieu I,
    7. et al.

    (2015) Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Res 17:49.

    OpenUrlPubMed